This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Rare Disease Conference 2024 - Rare Disease Summit
March 18-20, 2025
Pre-Conference Workshops on March 17, 2025Sheraton Philadelphia Downtown | Philadelphia, PA

Yves Dudal, Ph.D
CEO at Perseo Pharma


Bioengineer by training and with a PhD form Montreal Polytech, Dr. Yves Dudal has been heartedly engaged for the past 15 years in founding, funding, and growing 3 biotech startups in a scope ranging from ecodiagnostics, pharmaceutical biomanufacturing, and more recently, biopharmaceuticals development. Yves is currently the CEO of Perseo pharma, a Swiss preclinical stage startup company developing oral prophylactic drugs acting topically in the gut lumen for metabolic rare diseases. In his various ventures, and particularly at Perseo, Yves has experienced the great benefits of setting up early multiple partnerships with various stakeholders. He will discuss that today with us.

Agenda Sessions

  • Case Study - The Importance of Funding and Partnering from the Perspective of an Early Stage Biopharma Company